Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Clarksterh who wrote (1289)	11/1/2004 11:53:50 PM
From: marin	Read Replies (1) \| Respond to of 1386

"Marin - There is no further subdivision between GCS 4-6 and 7-8. Clark - I assume that they mean only that before unblinding that they do not know the breakdown? Not that the Statistical Analysis Plan will only group them that coarsely." The way I wrote that statement was out of context. At one time, there was a thought among investors that there would be a division between 4-6 and 7-8. What exactly that division would mean for the trial results I was never quite clear on, but Management never gave us that information as far as I know. But, anyway, that notion developed a life of its own and was refuted today by management. The trial outcome is GOSE at 6 months. It would have been interesting today, if management had given us the final MGCS average. It's funny, they didn't mind publicizing the average at around the 500 and 700 patient mark, but the trial is finished so they don't feel comfortable. Sigh... jonmarin

To: Clarksterh who wrote (1289)	11/12/2004 9:45:37 PM
From: rjk01	Read Replies (1) \| Respond to of 1386

Translation adlib from an Israeli analysis (S. Cohen)dated Nov 11. 1. While US institutions only “know” about Teva, all their Israeli contemporary hold both teva and pars in their file 2. Only one analysis in the US cover them (Dr. David B from CBR) 3. The reason the pps&volume up last few days is not due to the article published that week but rather the New Orleans conference and the SNY discovery on their cannabis based drug. That reminded some investors of pars platform and the potential attached. 4. Pars platform is much boarder with pain relief, cancer Tx, Parkinson dz, heart dz etc applications. 5. Pain relief application is generating new interest ala the current neg “issues” concerning the Cox-2 inhibitors. During the Oct conference Aviv made a comment (similar one was made the next day in the WSJ) warning about the cox-2 potential long-term danger. Applying that pars holds in its pipeline an alternative w/o the long-term severe side effect. Clinical trial starting next year. 6. In this same conference Aviv was asked how many shares his top mangers hold and his reply was “TOo LITTLE” (i.e. for their own good they might wan to buy/hold more!)